Sophie Bambuck is the former Global Chief Marketing Officer ... Mondelez), pharmaceuticals (Sanofi Aventis, Novo Nordisk), financial services (American Express, Goldman Sachs, JPMorgan Chase ...

Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...

Bernstein analyst Florent Cespedes maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK560.00. The company’s shares closed last Friday at ...

Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding ...

Oct 21 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a ...

Novo Nordisk A/S (NVO) investors who had anticipated that the stock could continue outperforming the market were likely disappointed. Accordingly, NVO has underperformed the S&P 500 (SPX ...

Novo Nordisk is a great business ... AbbVie became a stand-alone company in 2012 after it split from its former parent company, Abbott Laboratories. Since then, it has increased its payouts ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO ... AbbVie became a stand-alone company in 2012 after it split from its former parent company, Abbott Laboratories. Since then, it has increased ...

While Novo Nordisk and Lilly each carry encouraging prospects, I see one of these companies as the superior opportunity. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market ...

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too.

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk NVO. And retail traders should know. We noticed this today when the trades showed up on publicly available ...